Share on LinkedInShare on LinkedIn

ARTICLE · 16 JANUARY 2017

What Brexit Means For Life Sciences

Gowling WLG
Gowling WLG
Contributor
Gowling WLG

Gowling WLG

The firm The firm’s lawyers speak English, French, Russian and Ukrainian. The firm’s client base...

View firm profile
Explore more from Gowling WLG

This is borne out in our research, which reveals that companies in the life sciences sector are least likely to have changed their UK investment plans in the wake of Brexit.

GlobalInternational Law

It has been an active year for the UK life sciences sector, with the EU referendum seemingly having no immediate impact on deal activity. As companies in the sector mature and evolve, we have seen collaboration and consolidation driving M&A levels. In short, it appears to be business as usual. This is borne out in our research, which reveals that companies in the life sciences sector are least likely to have changed their UK investment plans in the wake of Brexit.

However, during the past two decades, many of these companies have been the recipients of important European funding and if this were no longer available in post-Brexit UK the shortfall would somehow need to be made up by the government or from the private sector.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from